Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
NCT04663750
Recruiting
The centre of the retina (macula) at the back of the eye contains cells that give us our central vision that we use for reading and recognising faces. These cells can be damaged by a disease called wet age-related macular degeneration (AMD), where new abnormal blood vessels grow through the macula and leak fluid. This can affect vision. In some cases, wet AMD can also cause a bleed under the macula, known as a submacular haemorrhage (SMH), which can lead to marked and persistent loss of vision i... Read More
Gender:
ALL
Ages:
Between 50 years and 120 years
Trial Updated:
08/01/2025
Locations: University Medical Center Hamburg Eppendorf, Hamburg, Not set +30 locations
Conditions: Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage
Register for Updates
PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]
NCT06923111
Recruiting
This post-authorisation safety and efficacy study (PRECISE PASS) evaluates the use of Xromi® (hydroxycarbamide 100 mg/mL oral solution) in children aged 9 months to under 2 years with sickle cell disease (SCD). The objective is to assess the safety profile and clinical effectiveness of Xromi® under routine clinical conditions. The study includes a prospective cohort of Xromi®-treated patients and a matched retrospective comparator cohort of untreated patients. Participants will be followed for... Read More
Gender:
ALL
Ages:
Between 9 months and 23 months
Trial Updated:
08/01/2025
Locations: Basildon University Hospital, Basildon, Essex +4 locations
Conditions: Sickle Cell Disease
Register for Updates
Salutare One Referral Software Impact on Multi-Disciplinary Team (MDT) Meetings Effectiveness and Safety
NCT07104955
Recruiting
Multi-Disciplinary Team (MDT) meetings are crucial for planning patient care in the National Health Service (NHS), but they can be time-consuming and sometimes lack complete patient information. This can lead to delays in treatment decisions, potentially incomplete care plans, or the need to repeatedly discuss the same patient cases. This study aims to test a new software called Salutare One Referral. One Referral is designed to make these meetings more efficient and effective. We want to see i... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/01/2025
Locations: Royal National Orthopaedic Hospital, London, Not set
Conditions: Cancer (Solid Tumors), Sarcoma
Register for Updates
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT06004245
Recruiting
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RO7589831 monotherapy, and in combination with pembrolizumab, in participants with microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) advanced solid tumors. RO7589831 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: City of Hope Cancer Center, Duarte, California +24 locations
Conditions: Advanced Solid Tumors
Register for Updates
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080
Recruiting
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/01/2025
Locations: Alaska Oncology & Hematology, LLC, Anchorage, Alaska +273 locations
Conditions: Large B-Cell Lymphoma
Register for Updates
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
NCT04774718
Recruiting
This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
08/01/2025
Locations: Lucile Packard Children's Hospital, Palo Alto, California +32 locations
Conditions: ALK Fusion-positive Solid or CNS Tumors
Register for Updates
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336
Recruiting
In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies. In the Main Study (including Phase 1a, Phase 1b, and Phase 2 portions), ziftomenib will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment. In Sub-studies 1 and 2, the effects of taking ziftomenib and other common drugs at the same time will be investigated in AM... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +55 locations
Conditions: Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
Register for Updates
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769
Recruiting
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
08/01/2025
Locations: UAB Lung Health Center, Birmingham, Alabama +458 locations
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
NCT05196035
Recruiting
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine. The kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood... Read More
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
08/01/2025
Locations: Phoenix Children's Hospital | Main - Transplant Department, Phoenix, Arizona +153 locations
Conditions: Chronic Kidney Disease, Proteinuria
Register for Updates
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204
Recruiting
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: University of South Alabama, Mobile, Alabama +179 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Low EnerGy DiEt iN Adolescents With Obesity and Type 2 Diabetes: The LEGEND Study
NCT06572345
Recruiting
This is a multicentre, single-arm, feasibility study in adolescents with T2DM and obesity to investigate the recruitment and retention rates to a study using Low Energy Diets(LED). It will also provide estimates of weight loss needed to bring about remission to inform a larger randomised study. In addition a subgroup of participants and their parents/carers undertaking a period of LED will be interviewed to understand the participants experience of taking part. Two further groups will also be in... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
08/01/2025
Locations: Nottingham University Hospital NHS Trust, Nottingham, Not set
Conditions: Pediatric Obesity, Type 2 Diabetes
Register for Updates
Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the NHS Care of Multiple Sclerosis
NCT07111637
Recruiting
Multiple Sclerosis (MS) is a long-term disease that affects over 150,000 people in the UK. Starting treatment early is important for managing MS. It is also essential to monitor the treatment to see if it is working and to switch treatments if needed. Magnetic resonance imaging (MRI) is the only accepted tool to monitor how well the treatment is working. Current evaluation of brain MRI scans requires visual inspection, of which sensitivity is degraded by human, and technical factors, such as la... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/01/2025
Locations: Barts Health NHS Trust, London, Not set
Conditions: Multiple Sclerosis
Register for Updates